Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
ID: ALA4528305
Max Phase: Preclinical
Molecular Formula: C53H87BN4O17
Molecular Weight: 1063.10
Molecule Type: Unknown
Associated Items:
ID: ALA4528305
Max Phase: Preclinical
Molecular Formula: C53H87BN4O17
Molecular Weight: 1063.10
Molecule Type: Unknown
Associated Items:
Canonical SMILES: CC[C@H]1OC(=O)[C@H](C)[C@@H](O[C@H]2C[C@@](C)(OC)[C@@H](OC(=O)NCCCNC(=O)CCc3cccc4c3B(O)OC4)[C@H](C)O2)[C@H](C)[C@@H](O[C@@H]2O[C@H](C)C[C@H](N(C)C)[C@H]2O)[C@](C)(O)C[C@@H](C)CN(C)[C@H](C)[C@H]2OC(=O)O[C@@]21C
Standard InChI: InChI=1S/C53H87BN4O17/c1-15-38-53(10)45(74-50(63)75-53)33(6)58(13)27-29(2)25-51(8,64)44(72-48-42(60)37(57(11)12)24-30(3)68-48)31(4)43(32(5)47(61)70-38)71-40-26-52(9,66-14)46(34(7)69-40)73-49(62)56-23-17-22-55-39(59)21-20-35-18-16-19-36-28-67-54(65)41(35)36/h16,18-19,29-34,37-38,40,42-46,48,60,64-65H,15,17,20-28H2,1-14H3,(H,55,59)(H,56,62)/t29-,30-,31+,32-,33-,34+,37+,38-,40+,42-,43+,44-,45-,46+,48+,51-,52-,53-/m1/s1
Standard InChI Key: GTTNKGAVEAXSTK-VRARGAMRSA-N
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Natural Product: No | Oral: No | Chemical Probe: No | Parenteral: No |
Molecule Type: Unknown | Topical: No | First In Class: No | Black Box: No |
Chirality: No | Availability: No | Prodrug: No |
MESH ID | MESH Heading | EFO IDs | EFO Terms | Max Phase for Indication | References |
---|
Mechanism of Action | Action Type | target ID | Target Name | Target Type | Target Organism | Binding Site Name | References |
---|
Molecular Weight: 1063.10 | Molecular Weight (Monoisotopic): 1062.6159 | AlogP: | #Rotatable Bonds: |
Polar Surface Area: | Molecular Species: | HBA: | HBD: |
#RO5 Violations: | HBA (Lipinski): | HBD (Lipinski): | #RO5 Violations (Lipinski): |
CX Acidic pKa: | CX Basic pKa: | CX LogP: | CX LogD: |
Aromatic Rings: | Heavy Atoms: | QED Weighted: | Np Likeness Score: |
1. Janas A, Przybylski P.. (2019) 14- and 15-membered lactone macrolides and their analogues and hybrids: structure, molecular mechanism of action and biological activity., 182 [PMID:31499358] [10.1016/j.ejmech.2019.111662] |
2. Fernandes GFS, Denny WA, Dos Santos JL.. (2019) Boron in drug design: Recent advances in the development of new therapeutic agents., 179 [PMID:31288128] [10.1016/j.ejmech.2019.06.092] |
Source(1):